Upgrades only matter if they carry weight, from a house/analyst that big money follows. That's exactly what we got here. Fireworks a comin'. And I only care if more upgrades come from those who carry weight.
here is article Motley Fool
A Look at Three Biotech Movers
By Brian Nichols - January 25, 2013 | Tickers: CLSN, SRPT, THLD | 0 Comments
Sarepta Therapeutics (NASDAQ: SRPT)
I bought shares of Sarepta back in November at $25.50, and I wouldn’t sell them for $55 today. However, $55 is the exact target that Cowen & Cowen are giving the stock, as it prepares for its meeting with the FDA to determine a course of action for the development of its drug eterplirsen.
. This is a stock that has been upgraded by virtually every analyst who covers the stock since announcing phase data for its Muscular Dystrophy drug back in October. The drug has been granted an Orphan status by the FDA and has the potential to reach prices in $100’s if approved.
The real upside for this stock is not just the approval of its drug eterplirsen, but rather its technology, pipeline, and the Orphan status. The drug itself has peak sales expectations of about $700 million: I say this is a definite “buy."